Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Marian Case

Newcastle AuthorsTitleYearFull text
Dr Dino Masic
Kayleigh Fee
Dr Hayden Bell
Marian Case
Juan Ojeda Garcia
et al.		Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia2023
Marian Case
Dr Dino Masic
Dr David Jamieson
Dr Frederik van Delft
Professor Andrew Filby
et al.		Label-Free Leukemia Monitoring by Computer Vision2020
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.		Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Dr Paul Sinclair
Dr Sarra Ryan
Dr Matthew Bashton
Shaun Hollern
Rebecca Hanna
et al.		SH2B3 inactivation through CN-LOH-12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain2019
Dr Britta Vormoor
Professor Gareth Veal
Melanie Griffin
Professor Julie Irving
Lynne Minto
et al.		A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia2017
Judith Weiland
Dr Deepali Pal
Marian Case
Professor Julie Irving
Dr Frida Ponthan
et al.		BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance2016
Dr Lindsay Nicholson
Elizabeth Matheson
Lynne Minto
Christopher Keilty
Maryna Sanichar
et al.		Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition2015
Professor Julie Irving
Elizabeth Matheson
Helen Blair
Marian Case
Isabella Swidenbank
et al.		Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-34302015
Professor Julie Irving
Elizabeth Matheson
Dr Helen Blair
Marian Case
Isabella Swidenbank
et al.		Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition2014
Dr Lindsay Nicholson
Elizabeth Matheson
Lynne Minto
Marian Case
Maryna Sanichar
et al.		Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia2012
Sarina Sulong
Professor Anthony Moorman
Professor Julie Irving
Marian Case
Professor Simon Bailey
et al.		A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups2009
Professor Julie Irving
Marian Case
Lynne Minto
Sally Lawson
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting2009
Kate Wilson
Marian Case
Lynne Minto
Professor Simon Bailey
Dr Nicholas Bown
et al.		Flow minimal residue disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhoood acute lymphoblastic leukemia2009
Kerrie Wilson
Dr Klaus Rehe
Dr Simon Bomken
Marian Case
Professor Julie Irving
et al.		In Childhood ALL, Both Blasts with a CD20(-/Low) and a CD20(High) Immunophenotype, Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y-/- Mice2008
Professor Anthony Moorman
Sarina Sulong
Professor Julie Irving
Marian Case
Lynne Minto
et al.		Inactivation of CDKN2A in childhood acute lymphoblastic leukaemia (ALL) occurs principally by deletion and is strongly correlated with cytogenetic subgroups2008
123